Walgreens Boots Alliance, Inc. vs Amneal Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Walgreens vs. Amneal: A Decade of Gross Profit Insights

__timestampAmneal Pharmaceuticals, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 201444963400021569000000
Thursday, January 1, 201549922600026753000000
Friday, January 1, 201659745500029874000000
Sunday, January 1, 201752617800029162000000
Monday, January 1, 201871640300030792000000
Tuesday, January 1, 201935299700028159000000
Wednesday, January 1, 202062839300026077000000
Friday, January 1, 202176897300028067000000
Saturday, January 1, 202278470800028266000000
Sunday, January 1, 202382056500027072000000
Monday, January 1, 202426524000000
Loading chart...

Unleashing insights

Walgreens Boots Alliance vs. Amneal Pharmaceuticals: A Decade of Gross Profit Trends

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of key players is crucial. Over the past decade, Walgreens Boots Alliance, Inc. has consistently outperformed Amneal Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, Walgreens maintained an average gross profit nearly 45 times greater than Amneal's, peaking in 2018 with a staggering $30.8 billion. In contrast, Amneal's highest gross profit was approximately $820 million in 2023, marking a 130% increase from its 2014 figures. Despite this growth, Amneal's financial trajectory remains dwarfed by Walgreens' robust performance. Notably, 2024 data for Amneal is missing, leaving a gap in the comparative analysis. This financial narrative underscores the competitive dynamics within the sector, highlighting Walgreens' dominant market position and Amneal's steady, albeit smaller, growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025